Evaluating KC1036 for treating advanced Ewing sarcoma in adolescents

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This open-label, single-arm clinical trial aims to assess the safety and effectiveness of KC1036 in adolescents aged 12 to 18 with advanced Ewing sarcoma. Participants will receive KC1036 once daily, with treatment cycles lasting four weeks. The study focuses on patients with unresectable or metastatic Ewing sarcoma who have exhausted standard treatment options. The trial will monitor the participants for measurable responses and overall health during the treatment period.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age between 12 and less than 18 years;
* Diagnosed with Ewing sarcoma confirmed by histopathological examination;
* Patients with locally advanced or metastatic Ewing sarcoma that is unresectable or has failed standard treatment, and for whom no other treatment options are available as assessed by the investigator;
* Body weight of ≥30 kg;
* Karnofsky performance status (≥16 years) or Lansky performance status (\<16 years) score of ≥60%;
* Patients with at least one measurable lesions according to RECIST v1.1 (Response Evaluation Criteria in Solid Tumors);
* Expected survival of more than 12 weeks;
* Sufficient organ and bone marrow function;
* Female patients who have started menstruating must have a negative pregnancy test;
* The patient and their legal guardians understand and are willing to participate in the trial, and have signed the informed consent form.

Exclusion Criteria:

* Patients with primary central nervous system tumors;
* Presence of central nervous system metastases as diagnosed by imaging;
* History of or concurrent other malignancies within the past 5 years;
* Gastrointestinal abnormalities;
* Cardiovascular or cerebrovascular abnormalities;
* Patients who have previously received VEGFR-TKI small molecule treatment;
* Currently participating in another therapeutic clinical trial; received any anticancer treatment within 2 weeks or 5 half-lives (whichever is longer) before the start of the study treatment; received whole-brain radiation therapy within 14 days before the start of the study treatment; received stereotactic radiosurgery within 7 days before the start of the study treatment; or received herbal or traditional Chinese medicine for anticancer purposes within 2 weeks before the study treatment;
* Underwent major surgery within 2 months before enrollment or have not fully recovered, or plan to undergo surgery during the current study period;
* Persistent toxicity from previous anticancer treatment that has not improved to ≤ Grade 1 (according to CTCAE v5.0), excluding alopecia;
* Unhealed skin wounds, surgical sites, traumatic sites, severe mucosal ulcers, or fractures;
* Uncontrolled significant pleural effusion, ascites, or pericardial effusion;
* Active bacterial, viral, or fungal infections; unexplained fever \>38.5°C within 2 weeks before enrollment;
* Hepatitis B surface antigen (HBsAg) positive with HBV-DNA ≥500 IU/mL or 2500 copies/mL; Hepatitis C virus (HCV) antibody positive with HCV RNA ≥200 IU/mL or positive test results; HIV-positive individuals;
* Presence of psychiatric or neurological disorders; or cognitive impairment;
* Fertile patients (e.g., females who have started menstruating or males who have started ejaculating) who do not agree to use contraception (e.g., birth control pills or condoms) during the study and for 6 months after the study ends;
* Patients with insufficient compliance as evaluated by investigator;
* The investigator believes that it is not suitable to patient in this clinical trial.

Where it's running

• Beijing Children's Hospital Affiliated to Capital Medical University
  Beijing, Beijing Municipality, China Recruiting

Study contacts

• Principal investigator: Huanmin Wang — Beijing Children's Hospital Affiliated to Capital Medical University
• Study coordinator: Xin Ni
• Email: nixin@bch.com.cn
• Phone: 010-88324973

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Dynamic ProGRP Changes During Ewing Sarcoma Treatment

  This study tests whether changes in serum ProGRP levels over time reflect how well newly diagnosed Ewing sarcoma responds to treatment.

  Recruiting Peking University People's Hospital · Beijing · NCT07725783

• Methionine-Reduced Diet in Solid Tumors (early-phase)

  A small pilot study will test whether a methionine-reduced diet can change blood levels in adults with various solid tumors who are receiving standard cancer therapy.

  Recruiting Early Phase 1 University of California, Irvine · Orange, California · NCT07628634

• Adaptive Proton Therapy for Pediatric Solid Tumors and Hodgkin Lymphoma

  This study tests a regular imaging approach to see if proton therapy plans for children with solid tumors or Hodgkin lymphoma should be updated during treatment.

  Recruiting St. Jude Children's Research Hospital · Memphis, Tennessee · NCT07514819

• Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma

  This trial tests whether adding eflornithine (DFMO) as extra or maintenance therapy can improve survival for young people with Ewing sarcoma or osteosarcoma.

  Recruiting at 3 sites Phase 2 Milton S. Hershey Medical Center · Tampa, Florida and 2 other locations · NCT07321912

• Xaluritamig for relapsed or refractory Ewing sarcoma in adults, adolescents, and children

  This trial will test xaluritamig in adults, adolescents, and children with relapsed or refractory Ewing sarcoma to find a recommended dose for expansion and check safety and tolerability.

  Recruiting at 13 sites Phase 1 Amgen · Los Angeles, California and 12 other locations · NCT07297979

• Hypofractionated radiation plus B7-H3 CAR T cells for children and young adults with relapsed sarcoma

  This will test whether short-course radiation given before B7-H3 CAR T-cell therapy is safe for children and young adults (≤21) with relapsed or refractory B7-H3–positive sarcomas.

  Recruiting Phase 1 St. Jude Children's Research Hospital · Memphis, Tennessee · NCT07222735

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.